New investors pool $120M to bankroll Allogene's off-the-shelf CAR-T pipeline in drive to stay in the lead
It was clear from Allogene Therapeutics’ day 1 that Arie Belldegrun and David Chang were in no shortage of investors eager to back their allogeneic CAR-T therapies: They gathered $300 million in short order from a syndicate that features Pfizer, TPG and Vida Ventures.
The pair of Kite vets have driven the point home again with a $120 million private financing announced Thursday morning as they worked to fill out the full team of execs who will run the show.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
